{
  "pmcid": "7160692",
  "sha256": "fac2258c472536d4ad61f85c185ca44e8644257041b94abaeeb589a66b902dab",
  "timestamp_utc": "2025-11-10T00:04:38.257724+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.98,
    "reading_ease": 11.41166666666669,
    "word_count": 240
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial Comparing Pancreaticojejunostomy and Pancreaticogastrostomy in High-Risk Postoperative Pancreatic Fistula Patients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomized controlled trial spanned from July 12, 2017, to March 15, 2019"
      },
      "Participants": {
        "score": 2,
        "evidence": "Adults undergoing elective pancreaticoduodenectomy with a high fistula risk score (7-10) were randomized to PJ or PG."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized to PJ or PG"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates whether pancreaticojejunostomy (PJ) or pancreaticogastrostomy (PG), both with externalized transanastomotic stent, is superior in reducing POPF incidence."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was POPF incidence, assessed postoperatively."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization used a computer-generated sequence with allocation concealment."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not implemented."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Of 604 screened, 72 were randomized (36 to PJ, 36 to PG)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "72 were randomized (36 to PJ, 36 to PG)."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "POPF incidence was not significantly different (PJ: 38.9%, PG: 50.0%; P = .48)."
      },
      "Harms": {
        "score": 1,
        "evidence": "PG was associated with higher Clavien-Dindo grade 3 or higher morbidity (47.2% vs 22.2%; P = .047)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: NCT03212196"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}